Last Thursday, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) approved CRISPR/Cas9 gene-edited therapy exagamglogene autotemcel (exa-cel). Will the FDA follow suit? What can patients expect the price tag to be?

Plus, a good handful of approvals for AstraZeneca, Pfizer and Astellas' Xtandi, and Keytruda.

Join BioSpace's Lori Ellis, Greg Slabodkin and Heather McKenzie as they discuss the news this week.